Ironwood Pharmaceuticals Release: Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C

Published: Sep 21, 2012

BARCELONA, Spain & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing approval for Constella® (linaclotide 290 micrograms), for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.

Back to news